LEQEMBI® is the newest Alzheimer’s drug. It is administered in hospitals via IV. Biogen applied to the FDA for approval of a home version using an “Autoinjector”. See how it works and learn its advantages.
The first doses of the newly approved Alzheimer’s drug “Leqembi” were administered in Louisville. More than 100 people have signed up since then. See why.
Biogen reprioritize resources allocated to ADUHELM® to advance LEQEMBI®.
At long last, we finally have a disease-modifying drug for Alzheimer’s. The FDA recently approved a new drug that promises to slow the progression of the disease. Only five Alzheimer’s treatments have been approved by the FDA up until a decade ago, and this is only the second to address the progression of the disease.
FDA-approved ADLARITY is the once-weekly donepezil patch. See how it compares to donepezil / Aricept / Ebixa tablets for Alzheimer’s.
A neuroradiologist at the Mayo Clinic in Jacksonville, FL warns that increased use of monoclonal antibody treatment for Alzheimer’s has also led to the discovery of amyloid-related imaging abnormalities — ARIA. Find out more.
The first drugs for Alzheimer’s disease emerged in the 1990s, but since then there has been a wave of clinical trial failures, major companies pulling resources from neuroscience R&D, and progress.
Dr. Robert Przybelski has prescribed lecanemab to real-life patients, and discusses his experience prescribing and administering the treatment.
Now, a third new Alzheimer’s drug expected to be approved by the Food and Drug Administration (FDA),. The field of new drugs is beginning to show progress in the fight to slow the disease.
The FDA has approved generic lecanemab (brand name Leqembi®). The new drug can slow the progression of Alzheimer’s. Two top doctors discuss the pros and cons.
Interestingly, loving care does not require twice the time. But it does require twice the presence.
A powerful song about an 80-year-old professor losing memory due to Alzheimer’s. A tribute and a call for understanding, love, and support.
The European Union authorizes Leqembi as its very first Alzheimer’s drug to target an underlying cause of Alzheimer’s.
Three important dementia studies focus on HS-AGING, a type of dementia almost as common as Alzheimer’s in the 85+ group. Yet few people have heard of it. Why? What makes it different?
An intriguing study of 120 grandmothers might surprise you. Doctors know socially engaged people have better cognition and less dementia. But can a person get too much of a good thing? What’s the right balance?
Enjoy this great duet between a musician with dementia and his son. A triumph of spirit over Alzheimer’s! Sing-a-long if you like!
It looks like a sneeze cannot give anyone Alzheimer’s. While Alzheimer’s abnormal disease proteins do spread from cell-to-cell, they are not “infectious”. Check out the facts.
No spam, only news and updates.
